YKYang Hee Kim

Yang Hee Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang Hee Kim has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of safety: In vitro reverse mutation and in vivo acute oral toxicity tests of three biomass products from amino acid-producing Corynebacterium glutamicum

    by Ji-Eun Park, Jiyeon Kim, MiNa Baek, Hyo-Jin An, Chan-Sung Park, Joon Young Jung, So-Young Kim, Yang Hee Kim

  • Open Access

    Toxicology and safety study of L‐tryptophan and its impurities for use in swine

    by Ji‐Eun Park, Soo Min Ko, Hyo‐Jeong Han, Ji‐Young Lee, Da Som Jeong, Dong Hyun Lee, In Kyung Heo, Yong Uk Shin, Yang Hee Kim, Woo‐Chan Son

    L‐tryptophan, an essential amino acid for physiological processes, metabolism, development, and growth of organisms, is widely utilized in animal nutrition and human health as a feed additive and nutritional supplement, respectively. Despite its known benefits, safety concerns have arisen due to an eosinophilia–myalgia syndrome (EMS) outbreak linked to L‐tryptophan consumed by humans. Extensive research has established that the EMS outbreak was caused by an L‐tryptophan product that contained certain impurities. Therefore, safety validations are imperative to endorse the use of L‐tryptophan as a supplement or a feed additive. This study was conducted in tertiary hybrid [(Landrace × Yorkshire) × Duroc] pigs to assess general toxicity and potential risks for EMS‐related symptoms associated with L‐tryptophan used as a feed additive. Our investigation elucidated the relationship between L‐tryptophan and EMS in swine. No mortalities or clinical signs were observed in any animals during the administration period, and the test substance did not induce toxic effects. Hematological analysis and histopathological examination revealed no changes in EMS‐related parameters, such as eosinophil counts, lung lesions, skin lesions, or muscle atrophy. Furthermore, no test substance‐related changes occurred in other general toxicological parameters. Through analyzing the tissues and organs of swine, most of the L‐tryptophan impurities that may cause EMS were not retained. Based on these findings, we concluded that incorporating L‐tryptophan and its impurities into the diet does not induce EMS in swine. Consequently, L‐tryptophan may be used as a feed additive throughout all growth stages of swine without safety concerns.


  • Open Access

    Toxicology and safety study of L‐tryptophan and its impurities for use in broiler feed

    by Soo Min Ko, Ji‐Eun Park, Ji‐Young Lee, Da Som Jeong, Jiyeon Kang, Kyu‐Yeol Son, In Kyung Heo, Yong Uk Shin, Yang Hee Kim, Woo‐Chan Son

    L‐tryptophan has been utilized as a feed additive in animal nutrition to improve growth performance, as well as a dietary supplement to alleviate various emotional symptoms in humans. Despite its benefits, concerns regarding its safety arose following the outbreak of eosinophilia‐myalgia syndrome (EMS) among individuals who consumed L‐tryptophan. The causative material of EMS was determined to be not L‐tryptophan itself, but rather L‐tryptophan impurities resulting from a specific manufacturing process. To investigate the effect of L‐tryptophan and its impurities on humans who consume meat products derived from animals that were fed L‐tryptophan and its impurities, an animal study involving broiler chickens was conducted. The animals in test groups were fed diet containing 0.065%–0.073% of L‐tryptophan for 27 days. This study aimed to observe the occurrence of toxicological or EMS‐related symptoms and analyze the residues of L‐tryptophan impurities in meat products. The results indicated that there was no evidence of adverse effects associated with the test substance in the investigated parameters. Furthermore, most of the consumed EMS‐causing L‐tryptophan impurities did not remain in the meat of broiler chickens. Thus, this study demonstrated the safety of L‐tryptophan and some of its impurities as a feed additive.


  • Safety concerns regarding impurities in L-Tryptophan associated with eosinophilia myalgia syndrome

    by Soo Min Ko, Ji-Eun Park, In Kyung Heo, Yong Uk Shin, Yang Hee Kim, Woo-Chan Son


  • Open Access

    Simultaneous determination of l-tryptophan impurities in meat products

    by Doo-Hee Lee, Yang Hee Kim, Mina Baek, In Kyung Heo, Yonguk Shin

    L-tryptophan has been used as a feed additive for swine and poultry and as a nutrient supplement for humans. However, some impurities in l-tryptophan have been reported as causative components of eosinophilia-myalgia syndrome. Therefore, from a safety perspective, it is important to analyze meat samples for these impurities. This study aims to develop an analytical method for the simultaneous detection of l-tryptophan impurities in meat products using LC–MS/MS. Among the various impurities, detection methods for (S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid (5-hydroxytryptophan) (HTP), 1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid (MTCA), 3a-hydroxy-1,2,3,3a,8,8a-hexahydropyrrolo-[2,3-b]-indole-2-carboxylic acid (PIC), and 1,1′-ethylidenebistryptophan (EBT) and 2-(3-indoylmethyl)-l-tryptophan (IMT) were developed. The developed method allowed simultaneous determination of these four impurities in 5 min. No interferences from the matrix were observed, and the method showed good sensitivity to each analyte. The method detection limit and limit of quantification in meat matrices were below 11.2 and 35.7 μg/kg, respectively.


  • Open Access

    Safety evaluation of dried L-tryptophan fermentation product in Sprague-Dawley rats

    by Soo Min Ko, Ji-Eun Park, Sang-Ho Kim, Myeong Kyu Park, Ja Kyung Seol, In Kyung Heo, Yong-Uk Shin, So-Young Kim, Yang Hee Kim, Woo-Chan Son


  • Open Access

    Metabolic Stability of D-Allulose in Biorelevant Media and Hepatocytes: Comparison with Fructose and Erythritol

    by Han-Joo Maeng, Jin-Ha Yoon, Kwang-Hoon Chun, Sung Tae Kim, Dong-Jin Jang, Ji-Eun Park, Yang Hee Kim, Seong-Bo Kim, Yu Chul Kim

    D-allulose, a C-3 epimer of D-fructose, is a rare monosaccharide used as a food ingredient or a sweetener. In the present study, the in vitro metabolic stability of D-allulose was examined in biorelevant media, that is, simulated gastric fluid (SGF) and fasted state simulated intestinal fluid (FaSSIF) containing digestive enzymes, and in cryopreserved human and rat hepatocytes. The hepatocyte metabolic stabilities of D-allulose were also investigated and compared with those of fructose and erythritol (a sugar-alcohol with no calorific value). D-allulose was highly stable in SGF (97.8% remained after 60 min) and in FaSSIF (101.3% remained after 240 min), indicating it is neither pH-labile nor degraded in the gastrointestinal tract. D-allulose also exhibited high levels of stability in human and rat hepatocytes (94.5–96.8% remained after 240 min), whereas fructose was rapidly metabolized (43.1–52.6% remained), which suggested these two epimers are metabolized in completely different ways in the liver. The effects of D-allulose on glucose and fructose levels were negligible in hepatocytes. Erythritol was stable in human and rat hepatocytes (102.1–102.9% remained after 240 min). Intravenous pharmacokinetic studies in rats showed D-allulose was eliminated with a mean half-life of 72.2 min and a systemic clearance of 15.8 mL/min/kg. Taken together, our results indicate that D-allulose is not metabolized in the liver, and thus, unlikely to contribute to hepatic energy production.


  • Open Access

    Supplementation of Non-Dairy Creamer-Enriched High-Fat Diet with D-Allulose Ameliorated Blood Glucose and Body Fat Accumulation in C57BL/6J Mice

    by Ga Young Do, Eun-Young Kwon, Yun Jin Kim, Youngji Han, Seong-Bo Kim, Yang Hee Kim, Myung-Sook Choi

    D-allulose, which has 70% of the sweet taste of sucrose but nearly no calories, has been reported to inhibit the absorption of lipids and suppress body weight gain in obese mice. Fats in non-dairy creamer consist of highly saturated fatty acids, which can cause various lipid disorders when consumed over a long period. We investigated whether D-allulose supplementation alleviates the effects of a non-dairy creamer-enriched high-fat diet on lipid metabolism. High-fat diets enriched with non-dairy creamer were administered to C57BL/6J mice with or without D-allulose supplementation for eight weeks by the pair-feeding design. Lipid metabolic markers were compared between the non-dairy creamer control group (NDC) and non-dairy creamer allulose group (NDCA). Body, adipose tissue, and liver weights, and fasting blood glucose levels, were significantly lower in the NDCA group than in the NDC group. Fecal fatty acid and triglyceride levels were significantly higher in the NDCA group than in the NDC group. Supplementing a non-dairy creamer-enriched high-fat diet with D-allulose improved overall lipid metabolism, including the plasma and hepatic lipid profiles, hepatic and adipose tissue morphology, and plasma inflammatory adipokine levels in mice. These results suggest that D-allulose can be used as a functional food component for preventing body fat accumulation from a high-fat diet that includes hydrogenated plant fats.


  • Open Access

    Gastrointestinal Tolerance of D-Allulose in Healthy and Young Adults. A Non-Randomized Controlled Trial

    by Youngji Han, Bo Ra Choi, So Young Kim, Seong-Bo Kim, Yang Hee Kim, Eun-Young Kwon, Myung-Sook Choi

    D-allulose has recently received attention as a sugar substitute. However, there are currently no reports regarding its association with gastrointestinal (GI) tolerance. Thus, we performed a GI tolerance test for D-allulose in order to establish its daily acceptable intake level. When the dose of D-allulose was gradually increased in steps of 0.1 g/kg·Body Weight (BW) to identify the maximum single dose for occasional ingestion, no cases of severe diarrhea or GI symptoms were noted until a dose of 0.4 g/kg·BW was reached. Severe symptoms of diarrhea were noted at a dose of 0.5 g/kg·BW. Similarly, the GI tolerance test did not show any incidences of severe diarrhea or GI symptoms until a dose of 0.5 g/kg·BW was reached. A correlation analysis of the GI tolerance test for D-allulose and sugar revealed significantly higher frequencies of symptoms of diarrhea (p = 0.004), abdominal distention (p = 0.039), and abdominal pain (p = 0.031) after D-allulose intake. Increasing the total daily D-allulose intake gradually to 1.0 g/kg·BW for regular ingestion resulted in incidences of severe nausea, abdominal pain, headache, anorexia, and diarrheal symptoms. Based on these results, we suggest a maximum single dose and maximum total daily intake of D-Allulose of 0.4 g/kg·BW and 0.9 g/kg·BW, respectively.


  • Open Access

    A Preliminary Study for Evaluating the Dose-Dependent Effect of d-Allulose for Fat Mass Reduction in Adult Humans: A Randomized, Double-Blind, Placebo-Controlled Trial

    by Youngji Han, Eun-Young Kwon, Mi Kyeong Yu, Seon Jeong Lee, Hye-Jin Kim, Seong-Bo Kim, Yang Hee Kim, Myung-Sook Choi

    D-allulose is a rare sugar with zero energy that can be consumed by obese/overweight individuals. Many studies have suggested that zero-calorie d-allulose has beneficial effects on obesity-related metabolism in mouse models, but only a few studies have been performed on human subjects. Therefore, we performed a preliminary study with 121 Korean subjects (aged 20–40 years, body mass index ≥ 23 kg/m2). A randomized controlled trial involving placebo control (sucralose, 0.012 g × 2 times/day), low d-allulose (d-allulose, 4 g × 2 times/day), and high d-allulose (d-allulose, 7 g × 2 times/day) groups was designed. Parameters for body composition, nutrient intake, computed tomography (CT) scan, and plasma lipid profiles were assessed. Body fat percentage and body fat mass were significantly decreased following d-allulose supplementation. The high d-allulose group revealed a significant decrease in not only body mass index (BMI), but also total abdominal and subcutaneous fat areas measured by CT scans compared to the placebo group. There were no significant differences in nutrient intake, plasma lipid profiles, markers of liver and kidney function, and major inflammation markers among groups. These results provide useful information on the dose-dependent effect of d-allulose for overweight/obese adult humans. Based on these results, the efficacy of d-allulose for body fat reduction needs to be validated using dual energy X-ray absorption.